These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6780634)

  • 1. Serum antibodies to capsular polysaccharide vaccine of group A Neissera meningitidis followed for three years in infants and children.
    Käyhty H; Karanko V; Peltola H; Sarna S; Mäkelä PH
    J Infect Dis; 1980 Dec; 142(6):861-8. PubMed ID: 6780634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization.
    Ceesay SJ; Allen SJ; Menon A; Todd JE; Cham K; Carlone GM; Turner SH; Gheesling LL; DeWitt W; Plikaytis BD
    J Infect Dis; 1993 May; 167(5):1212-6. PubMed ID: 8486957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses of human infants to three doses of group A Neisseria meningitidis polysaccharide vaccine administered at two, four, and six months of age.
    Gold R; Lepow ML; Goldschneider I; Draper TF; Gotschlich EC
    J Infect Dis; 1978 Dec; 138(6):731-5. PubMed ID: 105053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total and functional antibody response to a quadrivalent meningococcal polysaccharide vaccine among children.
    King WJ; MacDonald NE; Wells G; Huang J; Allen U; Chan F; Ferris W; Diaz-Mitoma F; Ashton F
    J Pediatr; 1996 Feb; 128(2):196-202. PubMed ID: 8636811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age.
    Peltola H; Mäkelä H; Käyhty H; Jousimies H; Herva E; Hällström K; Sivonen A; Renkonen OV; Pettay O; Karanko V; Ahvonen P; Sarna S
    N Engl J Med; 1977 Sep; 297(13):686-91. PubMed ID: 408682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Control of epidemic meningococcal meningitis by mass vaccination. II. Persistence of antibody four years after vaccination.
    Mohammed I; Onyemelukwe GC; Obineche EN; Gupta N; Oyeyinka GO
    J Infect; 1984 Sep; 9(2):197-202. PubMed ID: 6438245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Immunological effectiveness of a dried group-A meningococcal polysaccharide vaccine].
    Alliluev AP; Kotel'nikova OV; Chernyshova TF; Skirda TA; Kuvakina VI
    Zh Mikrobiol Epidemiol Immunobiol; 1984 Mar; (3):106-12. PubMed ID: 6428089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ELISA study of the antibody response after vaccination with a combined meningococcal group B polysaccharide and serotype 2 outer membrane protein vaccine.
    Rosenqvist E; Tjade T; Frøholm LO; Frasch CE
    NIPH Ann; 1983 Dec; 6(2):139-49. PubMed ID: 6427704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of O-acetyl-negative and -positive polysaccharide vaccines for infections with Neisseria meningitidis group C in infants.
    Pichichero M; Anderson P; Gotschlich E; Kamm J; McMullen A; Nielsen S
    J Infect Dis; 1985 Oct; 152(4):850-1. PubMed ID: 3930623
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
    Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
    Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics of antibody production to group A and group C meningococcal polysaccharide vaccines administered during the first six years of life: prospects for routine immunization of infants and children.
    Gold R; Lepow ML; Goldschneider I; Draper TF; Gotshlich EC
    J Infect Dis; 1979 Nov; 140(5):690-7. PubMed ID: 118997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The capsular polysaccharide of group B Neisseria meningitidis as a vehicle for vaccine development.
    Jennings HJ
    Contrib Microbiol Immunol; 1989; 10():151-65. PubMed ID: 2479499
    [No Abstract]   [Full Text] [Related]  

  • 13. Persistence of antibody following immunization of children with groups A and C meningococcal polysaccharide vaccines.
    Lepow ML; Goldschneider I; Gold R; Randolph M; Gotschlich EC
    Pediatrics; 1977 Nov; 60(5):673-80. PubMed ID: 411104
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Group C Neisseria meningitidis variant polysaccharide vaccines in children.
    Steinhoff MC; Lewin EB; Gotschlich EC; Robbins JB
    Infect Immun; 1981 Oct; 34(1):144-6. PubMed ID: 6795122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of the meningococcal vaccine from Group C capsular polysaccharide].
    González Enríquez J; García Comas L; Alcaide Jiménez JF; Sáenz Calvo A; Conde Olasagasti J
    Rev Esp Salud Publica; 1997; 71(2):103-26. PubMed ID: 9546855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interim report of a controlled field trial of immunization with capsular polysaccharides of Haemophilus influenzae type b and group C Neisseria meningitidis in Mecklenburg county, North Carolina (March 1974-March 1976).
    Parke JC; Schneerson R; Robbins JB; Schlesselman JJ
    J Infect Dis; 1977 Aug; 136 Suppl():S51-6. PubMed ID: 408433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent meningococcal meningitis due to partial complement defects and poor anti-meningococcal antibody response.
    Herva E; Leinonen M; Käyhty H; Mäkelä PH; Vetoniemi-Korhonen SL
    J Infect; 1983 Jan; 6(1):55-60. PubMed ID: 6411822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Observations on the immune responses of infants and young children to group A meningococcal polysaccharide vaccine].
    Zhao JW
    Zhonghua Liu Xing Bing Xue Za Zhi; 1983 Feb; 4(1):12-4. PubMed ID: 6411345
    [No Abstract]   [Full Text] [Related]  

  • 19. Persistence of antibodies to meningococcal IgA1 protease versus decay of antibodies to group A polysaccharide and Opc protein.
    Thiesen B; Greenwood B; Brieske N; Achtman M
    Vaccine; 1997 Feb; 15(2):209-19. PubMed ID: 9066040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis.
    Skevakis L; Frasch CE; Zahradnik JM; Dolin R
    J Infect Dis; 1984 Mar; 149(3):387-96. PubMed ID: 6425422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.